Clinical Application of Serum Tumor Associated Material (TAM) from Non-small Cell Lung Cancer Patients |
Li, Cheng-Guang
(Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University)
Huang, Xin-En (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) Xu, Lin (Department of Thoracic Surgery, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) Li, Ying (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) Lu, Yan-Yan (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) |
1 | Wu HX, et al (1983). Encyclopedia of Chinese Medical Oncology. Shanghai Science and Technology Press, 63 (Chinese). |
2 | Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8. |
3 | Zhang S, Cordon-Cardo C, Zhang HS, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: I.Focus on gangliosides. Int J Cancer, 73, 42-9. DOI |
4 | Zhang S, Zhang HS, Cordon-Cardo C, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer, 73, 50-6. DOI |
5 | Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50. |
6 | Zou X, Zhang XS, Sui L, et al (2004). Role of tulnor associated material (BXTM) in early diagnosing malignant tumor. Qilu J Med Laboratory Sci, 15, 4-6. |
7 | Meezan E, Wu HC, Black PH, et al (1969). Comparative studies on carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry, 8, 2518-24. DOI |
8 | Peracaula R, Tabarés G, Royle L, et al (2003). Altered glycosylation pattern allows the distinction between prostatespecifc antigen (PSA) from normal and tumor origins. Glycobiology, 13, 457-70. DOI |
9 | Orntoft TF, Vestergaard EM (1999). Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis, 20, 362-71. DOI |
10 | Pancino G, Osinaga E, Charpin C, et al (1991). Purification and characterization of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4. Brit J Cancer, 63, 390-8. DOI |
11 | Saussez S, Marchant H, Nagy N, et al (1998). Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer, 82, 252-60. DOI |
12 | Sell S (1990). Cancer-associated carbohydrates identified by monoclonal antibodies. Human Path, 21, 1003-19. DOI |
13 | Serum tumor associated material (TAM) testing kit, QINGDAO BO-XING Biotechnology Co., Ltd. http://www.cqtrueway.com. |
14 | Shriver Z, Raguram S, Sasisekharan R (2004). Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Disc, 3, 863-73. DOI |
15 | Taylor-Papadimitriou J, Epenetos AA (1994). Exploiting altered glycosylation patterns in cancer- progress and challenges in diagnosis and therapy. Trends Biotech, 12, 227-33. DOI |
16 | Turner GA (1992). N-Glycosylation of serum-proteins in disease and its investigation using lectins. Clin Chim Acta, 208, 149-71. DOI |
17 | Vinolas N, GalanMC, Casas F, et al (1998). Tumor markers inresponse monitoring and prognosis of non small cell lungcancer. Preliminaryreport Anticancer Res, 18, 631-4. |
18 | Hakomori S (2000). Traveling for the glycosphingolipid path. Glycoconj J, 17, 627-47. DOI |
19 | Gabius HJ (1988). Tumor lectinology- at the intersection of carbohydrate chemistry, biochemistry, cell biology, and oncology. Angew Chem, 27, 1267-76. DOI |
20 | Gehan EA, Tefft MC (2000). Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst, 92, 179-81. DOI |
21 | Hakomori S, Zhang Y (1997). Glycosphingolipid antigens and cancer therapy. Chem Biol, 4, 97-104. DOI |
22 | Hollingsworth MA, Swanson BJ (2004). Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer, 4, 45-60. DOI |
23 | Jiang M, Pu R (2010). Study on serum tumor related material (BXTM) with early diagnosis in malignant tumor. National Medical Frontiers of China, 5, 80-1. |
24 | Kim YJ, Varki A (1997). Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J, 14, 569-76. DOI |
25 | Kui Wong N, Easton RL, Panico M, et al (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem, 278, 28619-34. DOI |
26 | Liu ZM, et al (1986). Serum free proline and free hydroxyproline and its peptide-binding determination of hydroxyproline in the evaluation of bone tumors. Chinese J Laboratory Med, 9, 129-33 (Chinese). |
27 | MacDonald JS (1999). Carcinoembryonic antigen screening: Pros and cons. Sem Oncol, 26, 556-60. |
28 | Matsushita Y, Cleary KR, Ota DM, et al(1990).Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal-cancer metastases. Lab Invest,63, 780-91. |
29 | Dennis JW, Laferte S, Waghorne C, et al (1987). 1-6 branching of asn-linked oligosaccharides is directly associated with metastasis. Science, 236, 582-5. DOI |
30 | Basu PS, Majhi R, Batabyal SK (2003). Lectin and serum-PSA interaction as a screeninng test for prostate cancer. Clin Biochem, 36, 373-6. DOI |
31 | Deng H, Zhong BY, Peng GH, et al (2010). Application of Bo Xin SerumTumor Associated Material ( BXTM) in Malignant Tumor. Prac Prev Med, 17, 2493-5. |
32 | Diez M, Torres A, Maestro ML, et al (1996). Prediction of survival and recurrence by serum and cytosolic level sof CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer, 73, 1248-54. DOI |
33 | Foa P, Fornier M, Miceli R, et al (1999). Tumour markers CEA, NSE, SCC, TPA and CYFRA21.1 in resectable non-small cell lungcancer. Anticancer Res, 19, 3613-8. |